PLASMA CELL MYELOMA

This early-phase trial tests whether a vaccine made from a protein called survivin can safely boost the immune system to fight multiple myeloma. The study involves 18 patients who have already responded to initial treatment and are taking lenalidomide as maintenance therapy. The …

This study tests a new COVID-19 vaccine (GEO-CM04S1) in 63 adults with blood cancers like leukemia or lymphoma who have had a stem cell transplant or cell therapy. The goal is to see if this vaccine triggers a stronger immune response than standard mRNA vaccines, potentially offe…

This study offers continued access to the drug isatuximab for adults with multiple myeloma who are already benefiting from it after completing an earlier study. The main goal is to check the long-term safety of the drug. About 70 participants will be enrolled.

This study looks at whether people with multiple myeloma who have been in a deep remission (called MRD-negative) for at least 3 years can stop their maintenance therapy and just be monitored closely. The goal is to see if stopping treatment keeps the cancer under control for at l…

This study tests a new drug called iberdomide combined with three standard treatments (daratumumab, bortezomib, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to find the best dose and see if the combination can kill more cancer cells. About 49 a…

This study tests whether adding special immune cells called veto cells can help donor stem cells grow safely after a transplant for blood cancers. The goal is to prevent graft-versus-host disease, where donor cells attack the patient's body. About 16 people aged 12 to 75 with var…

This study tests whether a combination of belantamab mafodotin (a targeted chemotherapy) and lenalidomide can eliminate any remaining cancer cells in multiple myeloma patients who still have detectable disease after a stem cell transplant. The trial enrolls 4 adults with multiple…

This study tests whether adding elotuzumab to the standard maintenance drug lenalidomide can help prevent multiple myeloma from returning after a stem cell transplant. About 113 adults who recently had a transplant using their own stem cells will receive this combination therapy.…

This phase 3 study tests whether adding isatuximab to standard lenalidomide and dexamethasone can delay progression to active multiple myeloma in people with high-risk smoldering myeloma. About 337 participants will receive either the three-drug combo or the two-drug standard. Th…

This phase 3 trial compares two drug combinations (VRd and CRd) in 1087 people with newly diagnosed multiple myeloma. After initial treatment, participants receive either limited or indefinite maintenance therapy. The goal is to see which combination works better and how long mai…

This study tests whether the drug daratumumab, given after a stem cell transplant, can help keep multiple myeloma from coming back. About 31 adults with myeloma will receive daratumumab as a follow-up treatment. The goal is to see if this approach improves how long people stay ca…

This study tests whether adding isatuximab to a standard three-drug regimen (bortezomib, lenalidomide, and dexamethasone) can help people with newly diagnosed multiple myeloma who cannot have a stem cell transplant live longer without their cancer worsening. About 475 participant…

This study tests whether adding a drug called cyclophosphamide after a stem cell transplant can reduce the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The trial includes 35 adults with various blood cancers or seve…

This early-phase study tests whether giving healthy donor NK cells along with two medicines (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach, esophageal, or blood cancers. The NK cells are meant to attack cancer, but the b…

This study tests a decision-aid website that helps women with cancer understand their options for preserving fertility before starting treatment. About 130 women with breast, colorectal, or reproductive system cancers, lymphoma, or myeloma took part. The goal is to see if the web…

This study looks at how well the heart, lungs, and muscles work together in people who have had a stem cell transplant. Researchers want to find out why transplant survivors have a higher risk of heart disease. About 350 adults with blood cancers will be followed for two years af…